When administered at or near the initiation of experimental intracellular infection caused by Leishmania major, Toxoplasma gondii, or Cryptococcus neoformans, treatment with the immunoregulatory cytokine interleukin 12 (IL-12), induces protective antimicrobial activity. In contrast, once infections are established, IL-12 exerts considerably less or no effect in the face of a suppressive Th2 cell-associated response (L. major) or rapidly progressive fatal infection (T. gondii). To test the efficacy of IL-12 in an established intracellular protozoal infection but under quite different immunologic conditions (Thl cell response, acquired resistance), L. donovani-infected BALB/c mice were treated starting 2 wk after challenge coincident with the onset of the Thl cell response. In this environment, 7 d of IL-12 treatment reduced liver parasite burdens by 47%, an effect comparable to that induced by exogenous interferon (IFN) % The in vivo mechanism responsive to IL-12 was complex, and required both CD4 + and CD8 + T cells as well as natural killer cells and the action of multiple endogenous antileishmanial cytokines (IFN-% IL-2, tumor necrosis factor oe). Early treatment with IL-12 before the expression of the Thl cell response was also effective and induced an accelerated, near-cure response via an IFN-'lr-dependent mechanism. These results extend the antimicrobial-inducing capacity of IL-12 beyond prophylaxis by indicating that IL-12 can exert clear-cut therapeutic activity in an established intracellular infection.
N
'umerous recent reports have identified the pleiotropic cytokine, IL-12, as a critical component of the early events that initiate successful cell-mediated antimicrobial defense (1) (2) (3) . The role and/or effect of IL-12 has thus far been tested in four models of intraceUular infection caused by Le/shmania major (4, 5) , Toxoplasma gondii (6) (7) (8) , Listeria monocytogenes (9) , and Cyptococcus neoformans (10) . Results from these models suggest that the role of endogenous IL-12 and the treatment effect of exogenous IL-12 are both most prominent at or near the time infection is first introduced (4, 5, 7) . Indeed, when tested after the initial stage of host-parasite interaction in two of these models, IL-12 in exogenous form exerted considerably less activity in L. major infection (4, 5) and no effect in acute toxoplasmosis (7) . These latter results have prompted the impression that while IL-12 appears to be of clear-cut immunoregulatory importance (1-3) and effective early on or as prophylaxis (4) (5) (6) (7) 10) , there may nevertheless be a narrow therapeutic window for IL-12 in such infections.
Specific features of the preceding models of uncontrolled progressive infection (4, 5, 7) , however, likely influenced the efficacy of delayed IL-12 treatment: (a) the rapid establishment of an overwhelming and uniformly fatal infection in the acute T gondii model (7) , and (b) the prompt emergence of a particularly suppressive Th2 cell-assodated response which characterizes and propagates L. major infection in BALB/c mice (4, 5) . The results in these selected models, therefore, have left open the question of whether IL-12 can act therapeutically in other settings, for example, in an established but not fatal intracellular infection and/or in an intracellular infection associated with acquired resistance and a Thl cellrather than a Th2 cell-associated response. Since our model of visceral leishmaniasis fulfills these latter criteria (11, 12) , we treated L. donovani-infected BALB/c mice with IL-12 to test its in vivo activity under these quite different immunologic conditions.
Materials and Methods
Visceral Infection. 20-30-g female euthymic BALB/c and C57BL/6 beige mice (Charles River Breeding Laboratories, Wilmington, MA) and athymic (nude) BALB/c mice (Life Sciences, Inc., St. Petersburg, FL) were infected by tail vein with 1.5 x 107 L. donovani amastigotes maintained in hamsters (11) . Visceral infection was assessed microscopically in liver imprints, and liver parasite burdens are expressed as Leishman-Donovan units (LDU) (11) . Tissue granuloma development was examined using formalin-fixed, stained liver sections (11) .
Treatment with IL12 and IFN-T. Groups of three to five mice were treated for 7 d with 1 #g/d of murine rlL-12 (7.8 x 106 U/mg; Genetics Institute, Cambridge, MA) (4) and/or 2 x 10 s U/d of routine rlFN-'y (2 x 107 U/mg; Amgen Biologicals, Thousand Oaks, CA) suspended in saline containing 1 mg/ml of BSA (13) . Treatment was given continuously via subcutaneously implanted osmotic pumps (Alzet model 2001; Alza Corp., Palo Alto, CA) (12) which deliver drug for 7 d (12a). Preliminary experiments indicated that IL-12 delivered at 1 #g/d by pump for 7 d was as effective as seven consecutive daily intraperitoneal injections of 1 /~g of 1I.-12 (4, 5) (data not shown). Pumps were implanted 4 h after L. donovani challenge to test early (prophylactic) effects or 14 d after challenge to determine therapeutic activity in established infection. Treatment with pump-delivered saline/BSA alone had no effect as in prior studies (13) .
Treatment with Cell-defleting and Anticytokine Antibodies. Using previously described preparations and administration schedules (14-16) (see legends to Tables 1 and 2 and Fig. 1 ), IL-12-treated mice were injected intraperitoneally with: (a) 1 ml of hybridoma culture supernatants containing rat anti-mouse mAb GK1.5 (anti-CD4, American Type Culture Collection [ATCC, Rockville, MD] TIB 207, 8/~g/ml of IgG), 53-6.72 (anti-CD8, ATCC TIB 105, 11.6/~g/ml of IgG), and S4B6.1 (anti-IL-2, 12.5/~g/ml of IgG), or 25/~g of normal rat IgG (Sigma Chemical Co., St. Louis, MO); (b) 40/~1 of NK cell-depleting rabbit antiasialo GM1 antiserum (Wako Bioproducts, Richmond, VA) (15); or (c) 0.2 ml containing normal rabbit serum, rabbit anti-mouse TNF-~ antiserum (1.5 x 10 s neutralizing U/ml) (16), or rabbit anti-mouse IFN-3~ antiserum raised against routine rlFN-3,. At a dilution of 1:10,000, the latter preparation neutralized the activity of 10 U of rlFN-3, in an ELISA (Endogen Inc., Boston, MA). Fluorescence analysis of spleen cells (14) after three consecutive daily injections of anti-CD4 or anti-CD8 mAb indicated depletion of the targeted T call subset by 89-93% (data not shown).
Results and Discussion

Effect of lL-12 Treatment in Established Visceral Infection.
In euthymic BALB/c mice, L. donovani multiplies logarithmically within macrophages of the liver and spleen during the first 2-4 wk after challenge (11) . By week 4, T cell-dependent acquired resistance mediated by the Thl cell-associated cytokines, IFN-'y and IL-2 (12, 15, 17) , develops, visceral infection comes under control, and organ parasite burdens dedine (11) . To test the effect of IL-12 under these conditions in established visceral infection, pump treatment was begun 2 wk after L. donovani challenge and continued for 7 d. As shown in Table 1 " 2 wk after L. donovani infection, liver parasite burdens were determined, and pumps delivering 1/tg/d of IL-12 were then inserted on day 14. Anti-CD4, anti-CD8, and control rat IgG injections were given on days 11, 12, 13, 17, and 19 (14, 15) . Antiasialo GM1 antiserum and normal rabbit serum were injected on days 11 and 17 (14) . Results are from two to four experiments, and indicate mean _+ SEM values for (n) mice per group. * Percent killing = day 14 LDU -day 21 LDU + day 14 LDU x 100 (13). triggers the secretion of IFN-% IL-2, TNF-ot, and that acquired resistance involves the participation and interaction of each of these endogenous cytokines (15) (16) (17) . Since IL-12 can induce IFN-3, and IL-2 (1, 19) as weU as interact with IL-2 and TNF-o~ to enhance IFN-'y secretion (1, 19), we treated mice with various anticytokine preparations at the time of IL-12 administration. The results in Table 2 indicate that the leishmanicidal activity induced by IL-12 is multi-cytokine dependent and in a likely complex fashion (1, 19, 20) involves endogenous IFN-% IL-2, and TNF-ol. Weeks after infection dependent on IFN-q, (4, 5) . As shown in Fig. 1 A, early IL-12 treatment during week 1 only clearly enhanced control over visceral L. donovani; this effect was evident by week 2 and fully expressed by week 4. Although the effect of early IL-12 treatment was inhibited by simultaneous injections of anti-IFN-y ( Fig. 1 A) , administration of exogenous IFN-3' alone during week 1 did not achieve similarly sustained antileishmanial activity (Fig. 1 B) . This latter observation suggested effects of early IL-12 treatment in addition to the induction of endogenous IFN-3,.
Effect of Early
Together, these results indicate that IL-12 is active as treatment in a firmly established systemic intracellular infection caused by a pathogen that exclusively resides within visceral macrophages (11) . In view of the demonstrated role of endogenous IFN-3' in this model (17) and IFN-q,'s direct macrophage-activating leishmanicidal effects (13) , the capacity of IL-12 by itself or with IL-2 and TNF-ol to induce T cells and NK cells to secrete IFN-3' (1, 19, 20) seems likely to represent a primary action for IL-12. This conclusion, however, does not exclude the possibility that in established infection IL-12 treatment also further promotes or accelerates other effects of the generalized Thl cell-associated response which L. donovani infection provokes in this model (12, 15, 17) . Indeed, the capacity of early IL-12 treatment to act before the Thl cell response becomes detectable but still effectively influence the subsequent course of visceral infection supports other actions as well.
Controlled clinical trials have now shown IFN-3/to be an effective adjunct when used with conventional antimony chemotherapy in patients with visceral leishmaniasis (21, 21a) . Thus, the present results suggest that by acting as an inducer of endogenous IFN-% IL-12 may have also a future role as an adjunct to chemotherapy in the management of this and perhaps other IFN-3,-responsive intracellular infections (22) . Whether exogenous IL-12 can influence what appears to be a Th2 cell-associated response in human visceral leishmaniasis (23) (24) (25) and restore suppressed IFN-q,-generating capacity (23) are two important questions that remain to be tested.
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